RBGLY Overview

Award Recognition: CRYOPDP, part of DHL Health Logistics, won the SAP Digital Transformation Award for its blockchain-based platform, Atlas Path, developed in collaboration with Applied Blockchain at the 2025 Supply Chain Excellence Awards.

Innovative Technology: Atlas Path utilizes Silent Data's privacy-first blockchain infrastructure to enhance shipment visibility, proof of delivery, and compliance processes in healthcare logistics, ensuring real-time transparency and data protection.

Industry Impact: The implementation of Silent Data allows CRYOPDP to leverage blockchain technology while maintaining confidentiality and compliance, addressing privacy concerns that often hinder blockchain adoption in regulated industries.

Company Background: Applied Blockchain specializes in blockchain and privacy technologies, having developed over 150 platforms across various sectors, while CRYOPDP is a leader in temperature-controlled logistics for the life sciences and healthcare industries.

Analyst Recommendation: RBC Capital Markets has reiterated an "Outperform" rating for Reckitt Benckiser Group plc - Depositary Receipt (OTCPK:RBGLY) as of October 23, 2025, with a projected price target suggesting a 46.82% upside from its current price.

Projected Financials: The average one-year price target for RBGLY is $16.49/share, with a projected annual revenue increase of 16.96% and a non-GAAP EPS of 3.96.

Fund Sentiment: There has been a 24.14% increase in the number of funds reporting positions in RBGLY, with total shares owned by institutions rising by 14.79% over the last three months.

Shareholder Activity: Notable changes in shareholder positions include significant increases from Altrius Capital Management and Ramirez Asset Management, while some firms like AADEX and BINV have slightly decreased their holdings.

UBS Coverage and Price Target: UBS has reiterated a Buy recommendation for Reckitt Benckiser Group plc - Depositary Receipt (OTCPK:RBGLY) with an average one-year price target of $16.49/share, indicating a potential upside of 46.82% from its current price of $11.23/share.

Institutional Ownership Trends: There has been a notable increase in institutional ownership of Reckitt Benckiser, with 36 funds reporting positions, a 24.14% rise in the last quarter, and total shares owned by institutions increasing by 31.28% to 3,033K shares.

Zacks Rank Upgrade: Reckitt Benckiser Group PLC has been upgraded to a Zacks Rank #2 (Buy), indicating a positive earnings outlook and potential for stock price increase.

Earnings Estimates Impact: The upgrade reflects an upward trend in earnings estimates, which are closely correlated with stock price movements, particularly influenced by institutional investors.

Zacks Rating System: The Zacks rating system classifies stocks based on earnings estimate revisions, maintaining a balanced distribution of buy and sell ratings, with only the top 20% receiving favorable rankings.

Future Earnings Projection: For the fiscal year ending December 2025, Reckitt Benckiser is expected to earn $0.94 per share, with analysts raising estimates by 2.5% over the past three months.

Class Action Lawsuit: The Portnoy Law Firm is representing investors in a class action against Reckitt Benckiser Group PLC for alleged misleading statements regarding the health risks of their infant formula, Enfamil, during the period from January 13, 2021, to July 28, 2024. Investors have until August 4, 2025, to file a lead plaintiff motion.

Legal Allegations and Impact: The lawsuit claims Reckitt Benckiser failed to disclose risks associated with NEC for preterm infants using their formula, leading to significant stock price drops following jury verdicts against the company in related cases.

Class Action Notice: Shareholders of Reckitt Benckiser Group plc (RBGLY) are encouraged to register for a class action lawsuit due to allegations that the company misled investors regarding the risks associated with its Enfamil formula for preterm infants during the period from January 13, 2021, to July 28, 2024.

Next Steps for Shareholders: The deadline to seek lead plaintiff status is August 4, 2025, and registered shareholders will receive updates throughout the case lifecycle without any cost or obligation.